|Articles|June 1, 2002
Latanoprost plus brimonidine controls IOP
Austin, TX-Patients who need more than one ocular hypotensive agent to achieve low IOP may benefit more from a regimen of latanoprost (Xalatan, Pharmacia) and adjunctive brimonidine (Alphagan, Allergan) than from dual therapy with latanoprost and timolol, according to a recent study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
2
Topical liposomal ozonated oil may be a useful treatment in neurotrophic keratopathy
3
Screening for Demodex blepharitis: Integrating best practices into routine eye care
4
Seeing the difference: Multimodal imaging for AMD and GA
5



































